Cargando…
Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients
BACKGROUND: Small cell lung cancer (SCLC) is characterized by aggressive spread and poor prognosis, but has limited treatment options. Results of prognostic factors from randomized trials on treatment arrangement are conflicting and large‐scale real‐world analysis is lacking. METHODS: Patients diagn...
Autores principales: | Ma, Xiangjuan, Zhang, Ziran, Chen, Xiaoling, Zhang, Jie, Nie, Jun, Da, Ling, Hu, Weiheng, Tian, Guangming, Wu, Di, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Fang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201544/ https://www.ncbi.nlm.nih.gov/pubmed/33955685 http://dx.doi.org/10.1111/1759-7714.13846 |
Ejemplares similares
-
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
por: Chen, Xiaoling, et al.
Publicado: (2021) -
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020) -
Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019) -
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
por: Wang, Yang, et al.
Publicado: (2018) -
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
por: Wang, Yang, et al.
Publicado: (2021)